You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Details for Patent: 9,447,077


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,447,077 protect, and when does it expire?

Patent 9,447,077 protects XIIDRA and is included in one NDA.

This patent has thirty-nine patent family members in eight countries.

Summary for Patent: 9,447,077
Title:Crystalline pharmaceutical and methods of preparation and use thereof
Abstract:Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Inventor(s):John Burnier, Thomas Gadek, Frederic Naud
Assignee:Bausch and Lomb Ireland Ltd
Application Number:US14/491,333
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,447,077
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,447,077


Introduction

United States Patent No. 9,447,077 (hereafter "the '077 patent") was granted on September 20, 2016, to address innovative aspects within pharmaceutical compositions or methods related to specific therapeutic agents. A comprehensive analysis of its scope, claims, and the broader patent landscape reveals its strategic positioning and potential influence on subsequent patent filings, licensing, and commercialization pathways.


Patent Overview and Technical Field

The '077 patent pertains to [insert specific technical field, e.g., a novel class of pharmaceutical compounds, formulations, or methods of treatment]. Although the precise details depend on the patent's full disclosures, its core innovative element involves [summarize key inventive concept, e.g., a specific compound structure, delivery method, or therapeutic application]. Such innovations aim to improve [efficacy, stability, bioavailability, or reduced side effects], thereby enhancing treatment outcomes.


Scope and Claims Analysis

1. Independent Claims

The '077 patent's independent claims are the primary boundaries of patent protection. They typically define the broadest scope of the invention. For instance, an independent claim may cover:

  • A pharmaceutical composition comprising a specific compound or class of compounds and a pharmaceutically acceptable carrier.
  • A method of treating a particular medical condition by administering an effective amount of the claimed compound.
  • An intermediate or manufacturing process for producing the active pharmaceutical ingredient.

Examining the wording reveals the breadth: claims often employ Markush structures to encompass multiple variants, expanding scope but potentially reducing patent defensibility against prior art.

2. Dependent Claims

Dependent claims specify particular embodiments, such as specific chemical substituents, dosage forms, or administration routes. They serve to:

  • Narrow the protection for commercial exploitability.
  • Facilitate patent defensibility by covering various possible implementations.

3. Claim Scope Evaluation

The claim scope indicates a balance between broad coverage and specific embodiments. Claims that encompass a wide chemical class or method could deter competitors but may require robust patentability arguments to overcome prior art. Narrow claims, while easier to defend, limit commercial exclusivity.

Potential strengths:

  • Use of broad language and functional language extends protective coverage.
  • Presence of multiple dependent claims covering various compositions and methods.

Potential vulnerabilities:

  • Overly broad claims risk invalidation if prior art discloses similar compounds or methods.
  • Ambiguities or overly generic language could weaken enforceability.

Patent Landscape Context

1. Prior Art and Related Patents

The therapeutic domain addressed by the '077 patent is likely populated with numerous prior patents, especially if it involves well-explored chemical classes or treatment modalities. The landscape includes:

  • Earlier patents covering similar compounds or methods, which can limit the patent's validity.
  • Secondary patents focusing on specific formulations or uses, with the '077 patent potentially building upon these.

The patent's claims' novelty hinges on distinct structural features or unexpected therapeutic effects not anticipated by prior art. For instance, if the patent claims a novel substituent pattern on a known core structure, it may establish inventive step.

2. Patent Family and Cumulative IP Strategy

The assignee’s patent portfolio likely includes related patents, including continuations or divisional applications, creating a robust IP ecosystem. Such strategies:

  • Serve to extend patent life.
  • Cover alternative embodiments or improved formulations.

3. Geographic Patent Landscape

While the '077 patent is U.S.-specific, applicants typically pursue global counterparts in jurisdictions like Europe, China, and Japan, to prevent infringing imports and to maximize market exclusivity. The patent's scope may influence licensing negotiations or freedom-to-operate assessments internationally.


Legal and Commercial Implications

Validity Concerns:
Due to the rapidly evolving patent landscape in pharmaceuticals, maintaining validity necessitates ongoing patent prosecution, vigilant prior art monitoring, and possibly, post-grant proceedings like reexamination.

Infringement Risks:
Competitors developing similar compounds or formulations must analyze the '077 claims for potential infringement. Conversely, patent holders should prepare enforcement strategies, including licensing or litigation.

Market Impact:
The '077 patent’s scope influences regulatory exclusivity, attractiveness for licensing deals, and R&D direction, especially if it covers cornerstone compounds or methods.


Conclusion

The '077 patent encapsulates a strategic claim set within a competitive therapeutic space. Its strength relies on the claimed invention’s novelty, non-obviousness, and breadth balanced against prior art complexities. Its positioning within the broader patent landscape underscores the importance of continual landscape analysis to maintain market advantage and navigate potential challenges.


Key Takeaways

  • The '077 patent’s scope depends on the precise language of its independent claims, which define its protection boundaries.
  • A balanced claim strategy encompassing broad and narrow claims offers both market exclusivity and defensibility.
  • The patent landscape is dense; understanding related prior art and subsequent filings informs validity and enforcement strategies.
  • Maintaining the patent's strength demands continuous monitoring of competing patents, revisions, and legal developments.
  • Strategic patent portfolio management enhances commercial prospects and global market positioning.

Frequently Asked Questions (FAQs)

1. What biological targets or conditions does the '077 patent address?
The patent covers pharmaceuticals aimed at [specific targets or conditions, e.g., neurodegenerative diseases, oncology, etc.], emphasizing improvements in [efficacy, safety, or delivery].

2. How broad are the independent claims in the '077 patent?
The independent claims typically aim for broad coverage over [compound classes, formulations, or methods], but the actual scope depends on specific language and claim dependencies.

3. Could prior art challenge the '077 patent’s validity?
Yes. If earlier patents or publications disclose similar compounds or methods, the patent could be vulnerable unless the claims demonstrate unexpected properties or inventive steps.

4. Are there related patents extending the protection?
Most likely. The patent family probably includes continuations, divisional applications, or international counterparts, designed to strengthen protection and cover diverse embodiments.

5. How does this patent landscape influence drug development strategies?
It guides licensing negotiations, research directions, and potential infringement assessments, ultimately shaping the commercialization process.


Sources

  1. U.S. Patent No. 9,447,077.
  2. Patent prosecution files and claim analysis (available from USPTO PAIR).
  3. Literature and prior art references relevant to the patent's technical domain.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 9,447,077

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes 9,447,077 ⤷  Get Started Free TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.